The adeno-associated viral (AAV) vector appears to be the safest and most effective vehicle, allowing for long-term gene and protein expression after a single injection. There are 12 naturally occurring serotypes (AAV-1 to AAV-12) and over 100 variations of AAV, each having slightly different amino acid sequences, particularly within the hypervariable portions of the capsid proteins, and hence slightly different gene delivery capabilities.
Our team formulated a comprehensive strategy to conduct the study. Our scope covered clinical and pre-clinical research areas and in-depth analysis to generate actionable insights for our client. We identified emerging trends for AAV-based Gene Therapy, including regulatory elements explored in constructing an expression cassette for a practical therapeutic approach.
Our in-depth analysis of therapeutic candidates under various stages of development and corelating with their pre-clinical/ R&D focus of other players helped our client in understanding of key genetic constructs and their impact in gene therapy and performance on animal models. Furthermore, Identification of emerging trends and comparative analysis of R&D focus of key players in domain, proved to be valuable in making key decisions pertaining to their therapeutic portfolio and in improvising their research focus.